Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 16, 2023 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One’s portfolio of...
August 07, 2023 16:30 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG)...
June 12, 2023 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

BRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...
June 06, 2023 22:31 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Pricing of Public Offering of Common Stock

BRISBANE, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...
June 06, 2023 16:01 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
June 04, 2023 12:45 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in October 2023 ...
May 30, 2023 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

BRISBANE, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...
May 25, 2023 20:30 ET | Source: Day One Biopharmaceuticals, Inc.

CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), please note that in the second...
May 25, 2023 17:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Conference call and webcast scheduled on Sunday, June 4, 2023 at 6:00 p.m. CT BRISBANE, Calif., May 25,...
May 01, 2023 09:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team strengthened with executive appointments in clinical...